Race Oncology Appoints George Clinical for RC220 Bisantrene Phase 1 Trial

Race Oncology (ASX:RAC) appointed George Clinical International for the clinical development of RC220 bisantrene, a cardioprotective and anticancer drug for solid tumor patients, according to a Thursd

MT NewswiresJun 20 10:49

ASX Healthcare Stock Surges 11% on 'Incredibly Valuable' FDA News

Race Oncology Ltd (ASX: RAC) shares are roaring higher on Tuesday morning.

The Motley FoolJun 18 08:33

Race Oncology Receives US FDA Rare Pediatric Disease Designation for Leukemia Medication

Race Oncology (ASX:RAC) secured a rare pediatric disease designation from the US Food and Drug Administration for the use of the RC220 bisantrene medication to treat child patients with acute myeloid

MT NewswiresJun 18 07:49

Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%

Race Oncology (ASX:RAC) validated the efficacy of its bisantrene therapy medication to slow the progress of multiple myeloma, a form of blood cancer, in cell culture and mice models, according to a Th

MT NewswiresJun 13 10:21

Race Oncology Receives FDA Orphan Drug Designation Extension for Bisantrene RC220 | ASX:RAC, OTC:RAONF

Proactive InvestorsJun 11 22:41

Race Oncology Secures US FDA Orphan Drug Designation for Leukemia Medication; Shares Rise 5%

Race Oncology (ASX:RAC) secured an orphan drug designation from the US Food and Drug Administration for its proprietary bisantrene formulation, RC220, for use in potentially treating acute myeloid leu

MT NewswiresJun 11 09:13